-
公开(公告)号：US20230021717A1
公开(公告)日：2023-01-26
申请号：US17757212
申请日：2020-12-10
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Robert E DAVIS , Kimberly Vanover
IPC: C07D519/00
Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
-
![PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1HPYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE
FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC
DISORDERS](/abs-image/US/2024/01/04/US20240002403A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240002403A1
公开(公告)日：2024-01-04
申请号：US18240951
申请日：2023-08-31
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Robert E DAVIS , Kimberly Vanover
IPC: C07D519/00
CPC classification number: C07D519/00
Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I,
and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
-
Search Results
2
records
(took 0.012 seconds)
